Tags: Cancer | skin | cancer | test | squamous | cell | Lymphoseek

New Test Diagnoses Cancer Severity

Wednesday, 18 Jun 2014 12:25 PM


U.S. Food and Drug Administration approval for the Lymphoseek imaging agent (technetium 99m tilmanocept) has been expanded to include helping doctors determine if a type of cancer called squamous cell carcinoma has spread to the head and neck, and to what extent, the FDA said Friday.
The injected agent was first approved in 2013 to help doctors identify lymph nodes associated with breast cancer or melanoma skin cancer, the agency said in a news release.
For the newly approved use, the agent was evaluated in clinical study of 85 people with squamous cell carcinoma of the lip, mouth or skin. The most common side effects noted were injection-site pain and irritation.
Lymphoseek is marketed by Navidea Biopharmaceuticals, based in Dublin, Ohio.
 

© HealthDay

   
1Like our page
2Share
FDA-Approved-Drugs
U.S. Food and Drug Administration approval for the Lymphoseek imaging agent (technetium 99m tilmanocept) has been expanded to include helping doctors determine if a type of cancer called squamous cell carcinoma has spread to the head and neck, and to what extent, the FDA...
skin, cancer, test, squamous, cell, Lymphoseek
121
2014-25-18
Wednesday, 18 Jun 2014 12:25 PM
Newsmax Inc.
 

The information presented on this website is not intended as specific medical advice and is not a substitute for professional medical treatment or diagnosis. Read Newsmax Terms and Conditions of Service.

Newsmax, Moneynews, Newsmax Health, and Independent. American. are registered trademarks of Newsmax Media, Inc. Newsmax TV, and Newsmax World are trademarks of Newsmax Media, Inc.

NEWSMAX.COM
© Newsmax Media, Inc.
All Rights Reserved